Effects of long-term ingestion of LES001(Development code) targeted at female

Effects of long-term ingestion of LES001(Development code) targeted at female - Effects of long-term ingestion of LES001(Development code) targeted at female

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022135

Enrollment

Registered

2016-05-09

Start date

2016-05-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Ingestion of one active capsule twice a day within 30 minutes after breakfast and dinner for 7days. After washout about 3 weeks, ingestion of one placebo capsule twice a day within 30 minutes after br

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -Healthy female -A person with a stable menstrual cycle

Exclusion criteria

Exclusion criteria: -Subjects with an unstable menstrual cycle -Subjects with atopic dermatitis, eczema and pollen allergy -Subjects who are influenced by adhesion -Subjects with smoking habit -Subjects who have been suffered from a critical disease -Subjects with the illness of a vascular function -Subjects who are taking prescription medicine -Subjects deemed inappropriate to participate in this study by the principle investigator

Design outcomes

Primary

Measure	Time frame
Measurements of skin microcirculatory function and so on, before and after ingestion of LES001(Development code) for 7 days.	—

Countries

Japan

Contacts

Public ContactMayumi Ohtsuka

Kao Corporation R&D -Core Technology- Biological Science Research

ohtsuka.mayumi@kao.co.jp0285-68-7458

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026